---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-003323"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:51:53.104307+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arbutus announces positive Phase 2a data for imdusiran + VTP-300 in chronic HBV

## Summary
- Imdusiran + VTP-300 achieved statistically significant (p<0.05) lower HBsAg at 24 weeks post-EOT vs placebo.
- 80% treatment arm vs 16% placebo had HBsAg <100 IU/mL; 60% vs 0% <10 IU/mL at 24 weeks post-EOT.
- 84% of treatment arm patients met NA therapy discontinuation criteria vs 53% in placebo arm.
- Treatment generally safe; no SAEs or Grade 3/4 AEs; injection-site reactions and transient ALT increases.
- Additional cohort evaluating nivolumab combination fully enrolled; preliminary data expected H2 2024.

## SEC filing metadata
- accession: 0001171843-24-003323
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324003323/0001171843-24-003323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324003323/f8k_060524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-003323
- JSON: https://secwatch.observer/filing/0001171843-24-003323.json
- Plain text: https://secwatch.observer/filing/0001171843-24-003323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.